IPHA
Price
$2.19
Change
+$0.01 (+0.46%)
Updated
Aug 15 closing price
Capitalization
208.55M
31 days until earnings call
SLNO
Price
$71.63
Change
-$5.73 (-7.41%)
Updated
Aug 15 closing price
Capitalization
3.81B
80 days until earnings call
Interact to see
Advertisement

IPHA vs SLNO

Header iconIPHA vs SLNO Comparison
Open Charts IPHA vs SLNOBanner chart's image
Innate Pharma SA
Price$2.19
Change+$0.01 (+0.46%)
Volume$7.3K
Capitalization208.55M
Soleno Therapeutics
Price$71.63
Change-$5.73 (-7.41%)
Volume$7.29M
Capitalization3.81B
IPHA vs SLNO Comparison Chart in %
Loading...
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IPHA vs. SLNO commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IPHA is a Hold and SLNO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (IPHA: $2.19 vs. SLNO: $71.63)
Brand notoriety: IPHA and SLNO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IPHA: 63% vs. SLNO: 506%
Market capitalization -- IPHA: $208.55M vs. SLNO: $3.81B
IPHA [@Biotechnology] is valued at $208.55M. SLNO’s [@Biotechnology] market capitalization is $3.81B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IPHA’s FA Score shows that 1 FA rating(s) are green whileSLNO’s FA Score has 0 green FA rating(s).

  • IPHA’s FA Score: 1 green, 4 red.
  • SLNO’s FA Score: 0 green, 5 red.
According to our system of comparison, IPHA is a better buy in the long-term than SLNO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IPHA’s TA Score shows that 6 TA indicator(s) are bullish while SLNO’s TA Score has 4 bullish TA indicator(s).

  • IPHA’s TA Score: 6 bullish, 4 bearish.
  • SLNO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, IPHA is a better buy in the short-term than SLNO.

Price Growth

IPHA (@Biotechnology) experienced а +4.29% price change this week, while SLNO (@Biotechnology) price change was -13.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

IPHA is expected to report earnings on Sep 17, 2025.

SLNO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLNO($3.81B) has a higher market cap than IPHA($209M). SLNO YTD gains are higher at: 59.355 vs. IPHA (19.022).
IPHASLNOIPHA / SLNO
Capitalization209M3.81B5%
EBITDAN/A-194.63M-
Gain YTD19.02259.35532%
P/E RatioN/AN/A-
RevenueN/A0-
Total CashN/A290M-
Total DebtN/A52.8M-
FUNDAMENTALS RATINGS
IPHA vs SLNO: Fundamental Ratings
IPHA
SLNO
OUTLOOK RATING
1..100
4054
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
10048
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4551
P/E GROWTH RATING
1..100
33100
SEASONALITY SCORE
1..100
n/a25

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLNO's Valuation (73) in the Medical Specialties industry is in the same range as IPHA (76) in the null industry. This means that SLNO’s stock grew similarly to IPHA’s over the last 12 months.

SLNO's Profit vs Risk Rating (48) in the Medical Specialties industry is somewhat better than the same rating for IPHA (100) in the null industry. This means that SLNO’s stock grew somewhat faster than IPHA’s over the last 12 months.

SLNO's SMR Rating (98) in the Medical Specialties industry is in the same range as IPHA (98) in the null industry. This means that SLNO’s stock grew similarly to IPHA’s over the last 12 months.

IPHA's Price Growth Rating (45) in the null industry is in the same range as SLNO (51) in the Medical Specialties industry. This means that IPHA’s stock grew similarly to SLNO’s over the last 12 months.

IPHA's P/E Growth Rating (33) in the null industry is significantly better than the same rating for SLNO (100) in the Medical Specialties industry. This means that IPHA’s stock grew significantly faster than SLNO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IPHASLNO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 11 days ago
72%
Bullish Trend 6 days ago
87%
Declines
ODDS (%)
Bearish Trend 9 days ago
83%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CEBCF0.51N/A
N/A
China Everbright Bank Co Ltd.
ACCMF10.88N/A
N/A
AAC CLYDE SPACE AB
NWHUF3.45N/A
N/A
Northwest Healthcare Properties Real Estate Investment
JUMSF27.50N/A
N/A
Jumbo SA
CMPD4.25-0.15
-3.41%
CompuMed, Inc.

IPHA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IPHA has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IPHA jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHA
1D Price
Change %
IPHA100%
+0.65%
MDGL - IPHA
43%
Loosely correlated
-0.41%
SLNO - IPHA
34%
Loosely correlated
-7.41%
VALN - IPHA
30%
Poorly correlated
+10.12%
TNXP - IPHA
29%
Poorly correlated
-13.81%
QSI - IPHA
28%
Poorly correlated
-1.79%
More

SLNO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLNO has been loosely correlated with BRNS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SLNO jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLNO
1D Price
Change %
SLNO100%
-7.41%
BRNS - SLNO
56%
Loosely correlated
-2.81%
NKTX - SLNO
40%
Loosely correlated
+5.91%
RVMD - SLNO
40%
Loosely correlated
+0.83%
SYRE - SLNO
40%
Loosely correlated
+0.53%
IDYA - SLNO
39%
Loosely correlated
-0.16%
More